Cargando…

α4-integrin receptor desaturation and disease activity return after natalizumab cessation

OBJECTIVE: To describe the time course of α4-integrin receptor desaturation and disease activity return in patients with relapsing-remitting MS who discontinued natalizumab and to investigate baseline and on-study predictors for the recurrence of disease activity. METHODS: In the course of TOFINGO,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derfuss, Tobias, Kovarik, John M., Kappos, Ludwig, Savelieva, Marina, Chhabra, Richa, Thakur, Avinash, Zhang, Ying, Wiendl, Heinz, Tomic, Davorka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572051/ https://www.ncbi.nlm.nih.gov/pubmed/28856176 http://dx.doi.org/10.1212/NXI.0000000000000388

Ejemplares similares

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2008)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2010)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Exertional Desaturation Has Higher Mortality Than Non-Desaturation in COPD
por: Liu, Shih-Feng, et al.
Publicado: (2021)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
por: Nguyen Ky, Mélanie, et al.
Publicado: (2023)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
por: Hemmer, Bernhard, et al.
Publicado: (2023)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
por: Fox, Robert J., et al.
Publicado: (2014)

Acute desaturation in intubated patients
por: Myrianthefs, P, et al.
Publicado: (2011)

Guided Desaturation of Unactivated Aliphatics
por: Voica, Ana-Florina, et al.
Publicado: (2012)

Oxygen Desaturation during Endoscopy
por: Ismail, Abbas, et al.
Publicado: (1993)

Impact of complement activation on clinical outcomes in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2021)

Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose
por: Wiendl, Heinz, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

O041 The impact of including oxygen desaturations occurring during awake epochs on the oxygen desaturation index
por: Whenn, C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t7j4oggb4kdq4vmn5qqd3p9qgn